BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Premium Article

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

Plastic, Steel and Software: APAC’s Next-Generation Bioprocessing Choice

When a biologics manufacturer in Bengaluru, Songdo or Singapore signs off on a new production suite today, the hardest question is rarely which molecule to...

June 23, 2026 | Analysis

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap

There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...

June 15, 2026 | Analysis

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

Can AI close the MSK inequality gap? Improving access to musculoskeletal care in the UK

Behind these statistics lies a deeper and more troubling social divide: that the greatest burden is carried by those in our most deprived communities and m...

April 14, 2026 | Opinion | By Peter Grinbergs, Chief Medical Officer and Co‑founder of EQL

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Thermo Fisher Scientific Launches Gibco CHOvantage GS Cell Line Development Kit To Accelerate Biologics Development

Gibco CHOvantage GS Cell Line Development Kit delivers high productivity, streamlined timelines and royalty-free, clinical-stage licensing options to suppo...

April 02, 2026 | News

APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage

APAC Biopharma in Review: What Truly Moved the Needle This Year Asia-Pacific (APAC) has cemented its status as a pivotal biopharmaceutical hub in 2025, ma...

December 15, 2025 | Report

Takeda Steps Back from Cell & Gene Therapy to Refocus on Predictable Growth

Takeda Pharmaceutical, one of the world’s most globalised pharma companies, has confirmed it will step away from in-house development of its cell and...

October 05, 2025 | News

The $100 Billion Question: Can India Lead the Global Diabetes Economy?

India’s Diabetes Burden and Global Stakes: India is often called the “diabetes capital of the world,” and not without reason. Recent esti...

September 24, 2025 | Analysis | By editor@biopharmaapac.com

Could Early Lifestyle Interventions Change the Course of Type 2 Diabetes?

According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes. Of these, around 90% to 95% have Type 2 diabete...

September 18, 2025 | News

The State of Biotech and Life Science Jobs in Asia Pacific – 2025

In 2025, Asia-Pacific has emerged as the fastest-growing hub for biotech and life sciences employment, fuelled by a powerful combination of government supp...

September 09, 2025 | Report

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Stay Connected